Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
31.31
-0.18 (-0.57%)
At close: Nov 14, 2025, 4:00 PM EST
31.29
-0.02 (-0.06%)
After-hours: Nov 14, 2025, 4:10 PM EST
Galapagos NV Revenue
Galapagos NV had revenue of 71.16M EUR in the quarter ending September 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to 286.92M, up 10.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
286.92M EUR
Revenue Growth
+10.31%
P/S Ratio
6.21
Revenue / Employee
407,558 EUR
Employees
704
Market Cap
2.09B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GLPG News
- 9 days ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Galapagos to Present New Data from Cell Therapy Program at ASH 2025 - GlobeNewsWire
- 23 days ago - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors - GlobeNewsWire
- 26 days ago - Biotech firm Galapagos to wind down cell therapy business - Reuters
- 26 days ago - Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation - GlobeNewsWire
- 4 weeks ago - Galapagos Announces Appointment of Fred Blakeslee as General Counsel - GlobeNewsWire
- 6 weeks ago - Biotechnology firm Galapagos receives offers for cell-therapy business - Reuters
- 6 weeks ago - Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business - GlobeNewsWire